ALT5 Sigma Corp.
ALTS
Get informed when a big investor buys or sells
+ FollowMarket Cap$31.66B
Close$
$0.42
51.2% downside
Current Fair Value
51.2% downsideOvervalued by 51.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $31.66 Billion |
|---|---|
| Enterprise Value | $31.48 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.91 |
| Beta | 2.01 |
| Outstanding Shares | 126,818,888 |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | -0.18 |
|---|---|
| PEG | -0.03 |
| Price to Sales | - |
| Price to Book Ratio | 0.43 |
| Enterprise Value to Revenue | 2410.83 |
| Enterprise Value to EBIT | -418.83 |
| Enterprise Value to Net Income | -447 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
$15.31 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$15.46 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4653▲ 5.98% |
|---|---|
| Total Calls | 670,600▲ 36.02% |
| Total Puts | 312,000▲ 56.08% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.75%▲ 15.46% |
|---|---|
| Total Invested | $56.14M▼ 1.78% |
| Investors Holding | 95▲ 10.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...